Get the Stockscreener App
4.56
3.40%
0.15
Pre-market:
4.48
-0.08
-1.75%
Humacyte Inc stock is traded at $4.56, with a volume of 2.26M.
It is up +3.40% in the last 24 hours and down -1.72% over the past month.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.
See More
Previous Close:
$4.41
Open:
$4.45
24h Volume:
2.26M
Relative Volume:
0.48
Market Cap:
$586.73M
Revenue:
-
Net Income/Loss:
$-110.78M
P/E Ratio:
-4.2617
EPS:
-1.07
Net Cash Flow:
$-75.59M
1W Performance:
+10.68%
1M Performance:
-1.72%
6M Performance:
-39.60%
1Y Performance:
+70.79%
1-Day Range:
$4.39
$4.615
1-Week Range:
$4.02
$4.665
52-Week Range:
$2.689
$9.97
Humacyte Inc Stock (HUMA) Company Profile
Name
Humacyte Inc
Sector
Industry
Phone
919-313-9633
Address
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Compare HUMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
4.56 | 586.73M | 0 | -110.78M | -75.59M | -1.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-11-23 | Initiated | H.C. Wainwright | Buy |
| Aug-14-23 | Upgrade | Piper Sandler | Underweight → Neutral |
| Jun-22-23 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-22 | Downgrade | Piper Sandler | Overweight → Underweight |
| Oct-29-21 | Initiated | Cowen | Outperform |
| Sep-24-21 | Initiated | Oppenheimer | Outperform |
| Sep-22-21 | Initiated | BTIG Research | Buy |
| Sep-16-21 | Initiated | Piper Sandler | Overweight |
View All
Humacyte Inc Stock (HUMA) Latest News
DEADLINE ALERT for WOLF, HUMA, XRX, and ZETA: The Law - GlobeNewswire
DEADLINE ALERT for WOLF, HUMA, XRX, and ZETA: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders - GlobeNewswire Inc.
Humacyte (NASDAQ:HUMA) Given Buy Rating at D. Boral Capital - MarketBeat
Humacyte moves to test bioengineered vessel in heart surgery - Investing.com
Humacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting - The Manila Times
11,105 Shares in Humacyte, Inc. (NASDAQ:HUMA) Acquired by Brookstone Capital Management - Defense World
Humacyte (NASDAQ:HUMA) Stock Price Up 10%Time to Buy? - MarketBeat
Cantor Fitzgerald Boosts Earnings Estimates for Humacyte - Defense World
Humacyte FY2024 EPS Forecast Raised by Cantor Fitzgerald - MarketBeat
Humacyte (NASDAQ:HUMA) Stock Price Down 6.4%What's Next? - MarketBeat
Class Action Filed Against Humacyte, Inc. (HUMA)January 17, 2 - GuruFocus.com
HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
HUMA DEADLINE TODAY: ROSEN, A TOP RANKED LAW FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action - GlobeNewswire Inc.
HUMA Deadline: Rosen Law Firm Urges Humacyte, Inc. (NASDAQ: HUMA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights - Business Wire
Cantor Fitzgerald Forecasts Stronger Earnings for Humacyte - MarketBeat
Humacyte, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsHUMA - PR Newswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte - Markets Insider
Faruqi & Faruqi Reminds Humacyte Investors of the Pending - GlobeNewswire
Humacyte, Inc. Class Action: Levi & Korsinsky Reminds Humacyte, - GuruFocus.com
Shareholders that lost money on Humacyte, Inc.(HUMA) should - GlobeNewswire
Humacyte, Inc. (NASDAQ:HUMA) Short Interest Update - MarketBeat
Humacyte, Inc. (HUMA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
HUMA Lawsuit Alert! Class Action Against Humacyte, Inc. - TipRanks
The Gross Law Firm Notifies Shareholders of Humacyte, Inc.(HUMA) of a Class Action Lawsuit and an Upcoming Deadline - Marketscreener.com
Humacyte, Inc. (NASDAQ:HUMA) Receives $13.71 Consensus Target Price from Analysts - MarketBeat
Analysts Set Humacyte, Inc. (NASDAQ:HUMA) Price Target at $13.71 - Defense World
HUMA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - AccessWire
The Gross Law Firm Reminds Humacyte, Inc. Investors of the - GlobeNewswire
Deadline Soon: Humacyte, Inc. (HUMA) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit - Business Wire
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates C - GuruFocus.com
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Humacyte, Inc. of Class Action Lawsuit and Upcoming DeadlinesHUMA - PR Newswire
HUMA DEADLINE: TOP RANKED ROSEN LAW FIRM Encourages Humacyte, Inc. Investors to Secure Counsel - The Bakersfield Californian
symbol__ Stock Quote Price and Forecast - CNN
Humacyte (NASDAQ:HUMA) Trading Down 6.4%Should You Sell? - MarketBeat
Humacyte (NASDAQ:HUMA) Given “Buy” Rating at D. Boral Capital - Defense World
Contact Levi & Korsinsky by January 17, 2025 Deadline to Join Class Action Against Humacyte, Inc.(HUMA) - Morningstar
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 17, 2025 in Humacyte, Inc. LawsuitHUMA - AccessWire
HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securitie - GuruFocus.com
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
HUMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - AccessWire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte - StreetInsider.com
Investors in Humacyte, Inc. Should Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your RightsHUMA - AccessWire
HUMACYTE, INC. (NASDAQ: HUMA) DEADLINE ALERT: Bernstein - GlobeNewswire
HUMACYTE, INC. (NASDAQ: HUMA) DEADLINE ALERT: Bernstein Liebhard - WICZ
Humacyte, Inc. Sued for Securities Law Violations – - GlobeNewswire
Humacyte's (HUMA) "Buy" Rating Reiterated at D. Boral Capital - MarketBeat
Humacyte provides update on commerical launch, pricing of Symvess - TipRanks
Humacyte Provides Update on Commercial Launch and Pricing of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma - The Manila Times
Humacyte, Inc. (NASDAQ:HUMA) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Humacyte, Inc. (NASDAQ:HUMA) Position Increased by Barclays PLC - Defense World
Humacyte Inc Stock (HUMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):